stockrow
Friday 6 November 2026
Export TRLV’s income statement to Excel — free account
Trulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
11.07
0.53
−4.57%
Follow TRLV
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 6 | 5 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 207.75 | 207.75 |
P/S ratio |
1.41 | 0.83 | 0.86 | 1.12 | 3.89 | 0.00 |
Altman Z-Score |
0.98 | 0.70 | 0.42 | 1.08 | 2.37 | — |
P/FCF ratio |
7.98 | 8.21 | 6.63 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
1.09 | 1.20 | 0.68 | 2.10 | 3.00 | — |
Beneish M-Score |
(2.99) | (1.79) | (3.46) | (3.02) | — | — |
P/Operating CF |
28.08 | 32.08 | 7.42 | 24.88 | (58.30) | 91.54 |
P/B ratio |
1.45 | 0.79 | 0.69 | 0.71 | 1.69 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 129.72 | 9.04 | 12.05 | 0.00 |
EV/Sales |
1.44 | 1.04 | 1.16 | 1.53 | 4.21 | 0.00 |
EV/EBITDA |
5.36 | 4.65 | 0.00 | 7.89 | 13.91 | 0.00 |
EV/Operating CF |
6.23 | 4.53 | 6.48 | 80.56 | 304.42 | 0.00 |
EV/FCF |
8.15 | 10.25 | 8.90 | (11.70) | (16.88) | 0.00 |
Quick Ratio |
2.16 | 2.30 | 1.87 | 1.05 | 1.43 | — |
Current Ratio |
4.43 | 4.37 | 4.16 | 2.82 | 3.10 | — |
Net Debt/EBITDA |
0.11 | 0.93 | (6.53) | 2.09 | 1.07 | 0.00 |
Debt/Assets |
10.82% | 18.97% | 19.81% | 20.76% | 15.67% | — |
Debt/Equity |
0.26 | 0.44 | 0.38 | 0.37 | 0.25 | — |
Asset Turnover |
0.42 | 0.42 | 0.37 | 0.36 | 0.00 | 0.00 |
Operating CF/Net income |
(2.34) | (1.75) | (0.38) | (0.09) | 0.72 | 1.58 |
Capex/Depreciation |
(0.35) | (0.89) | (0.30) | (0.99) | (3.14) | (4.70) |
Interest Coverage |
2.26 | 1.57 | (2.72) | 0.68 | 7.01 | 10.79 |
| (9.73%) | (11.67%) | (31.58%) | (12.08%) | 0.00% | 0.00% | |
| (4.18%) | (5.54%) | (17.19%) | (7.22%) | 0.00% | 0.00% | |
ROIC |
7.61% | 4.09% | (7.95%) | 1.30% | 5.21% | 0.00% |
Return on Tangible Assets |
(10.52%) | (13.12%) | (50.71%) | (21.84%) | 1.59% | 0.00% |
Average Days of Receivables |
5.86 | 5.63 | 2.17 | 1.95 | 3.37 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
37.69% | 43.02% | 34.20% | 36.70% | 33.41% | 29.81% |
Intangible Assets out of Total Assets |
0.48 | 0.47 | 0.51 | 0.52 | 0.54 | 0.00 |
Share Based Compensation of Revenue |
1.73% | 1.70% | 0.94% | 1.49% | 0.99% | 0.53% |
Graham Net Nets |
(0.60) | (1.03) | (0.86) | (0.64) | (0.20) | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 6.59 | 0.00 |
Earnings Yield |
(7.16%) | (16.31%) | (54.67%) | (18.46%) | 0.48% | 0.48% |
Free Cash Flow Yield |
12.53% | 12.18% | 15.08% | (11.62%) | (6.42%) | 0.00% |
Revenue per Share |
6.17 | 6.24 | 5.98 | 6.48 | 6.69 | 4.59 |
Operating CF per Share |
1.43 | 1.43 | 1.07 | 0.12 | 0.09 | 0.88 |
Capex per Share |
(0.32) | (0.78) | (0.27) | (0.98) | (1.76) | (1.25) |
Free Cash Flow per Share |
1.11 | 0.65 | 0.80 | (0.86) | (1.67) | (0.37) |
Cash per Share |
1.34 | 1.58 | 1.10 | 1.14 | 1.67 | 0.00 |
Shareholders Equity per Share |
5.97 | 6.57 | 7.45 | 10.25 | 15.41 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.97 | 6.57 | 7.45 | 10.25 | 15.41 | 0.00 |
Free Cash Flow |
212.31 | 123.82 | 150.99 | (160.92) | (232.66) | (42.28) |
Working Capital |
435.77 | 466.07 | 362.50 | 383.25 | 355.48 | — |
Capital Expenditures |
(60.51) | (147.66) | (50.85) | (184.02) | (245.56) | (141.93) |
Net Current Asset Value |
(990.37) | (1,016.68) | (843.09) | (879.16) | (739.08) | — |
EV/EBIT |
11.84 | 12.56 | 0.00 | 37.09 | 19.24 | 0.00 |
Capex to Sales |
0.05 | 0.12 | 0.05 | 0.15 | 0.26 | 0.27 |
Price to Operating Income |
11.59 | 10.07 | 0.00 | 27.28 | 17.76 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
0.26 | 0.23 | 0.25 | 0.25 | 0.10 | 0.00 |
Cash ROIC |
12.56% | 5.91% | 7.00% | (5.65%) | (7.98%) | 0.00% |
Accounts Receivable Turnover |
63.42 | 94.92 | 170.96 | 161.27 | 0.00 | 0.00 |
Accounts Payable Turnover |
5.32 | 5.31 | 6.55 | 6.02 | 0.00 | 0.00 |
Inventory Turnover |
1.98 | 2.12 | 2.21 | 2.18 | 0.00 | 0.00 |
Average Days of Payables |
64.19 | 72.91 | 56.15 | 56.58 | 93.71 | 0.00 |
Days of Inventory on Hand |
188.16 | 179.40 | 143.90 | 190.75 | 209.74 | 0.00 |
Average Receivables |
18.63 | 12.50 | 6.61 | 7.55 | — | — |
Average Payables |
88.35 | 88.60 | 82.59 | 87.91 | — | — |
Average Inventory |
236.83 | 222.25 | 244.81 | 243.22 | — | — |
Average Assets |
2,783.18 | 2,799.66 | 3,064.73 | 3,405.89 | — | — |
Average Common Equity |
1,196.02 | 1,328.82 | 1,668.16 | 2,037.54 | — | — |
Columns are period end dates · fundamentals updated 5 Nov 2026